Neurocrine banks $20M as endometriosis drug advances to PhIII

Abbott Labs and Neurocrine Biosciences ($NBIX) recently sat down with FDA regulators to outline plans for a late-stage study of their experimental endometriosis drug elagolix, triggering a $20 million milestone payment to the biotech. "This represents another significant step forward for the elagolix program as it readies for pivotal studies and we remain confident that Abbott has the right resources devoted to elagolix to enable it to be both a clinical and commercial success," said Neurocrine CEO Kevin Gorman. Release

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.